Top Markets
Coin of the day
Hubei Biocause Pharmaceutical Co., Ltd. Hubei Biocause Pharmaceutical Co., Ltd.

Hubei Biocause Pharmaceutical Co., Ltd.

000627
주식 순위 #9082
Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a... Hubei Biocause Pharmaceutical Co., Ltd., based in Jingmen, China, operates a multifaceted business. Its primary activities within China involve the provision of life and motor insurance policies. Additionally, the company is engaged in the pharmaceutical, chemical, and new energy fuel industries. Specifically, in the pharmaceutical field, it conducts contract research, development, and manufacturing of active pharmaceutical ingredients (APIs), intermediate compounds, and various drug forms such as tablets, granules, and capsules. Its chemical offerings include substances like dimethyl ether gas and a-chloropropionyl chloride. The firm also boasts an international presence, distributing its products to markets including the United States, the European Union, and other global locations.
주가
$0.2219522
마지막 동기화: 2025-09-11
시가총액
$1.10B
변동 (1일)
0.04%
변동 (1년)
0.17%
국가
CN
거래 Hubei Biocause Pharmaceutical Co., Ltd. (000627)
Hubei Biocause Pharmaceutical Co., Ltd. (000627)의 수익
Sep 2024 기준 수익 TTM: $-246.31M
Hubei Biocause Pharmaceutical Co., Ltd.의 최신 재무 보고서에 따르면 회사의 현재 수익은 $-246.31M입니다. 2022년에 회사는 $32.59M의 수익을 올렸으며 이는 2021년의 수익 $53.98M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
Hubei Biocause Pharmaceutical Co., Ltd.의 수익 기록 (2000 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $-246.31M -6.66%
2023 $-263.90M -909.84%
2022 $32.59M -39.64%
2021 $53.98M -75.67%
2020 $221.88M -57.48%
2019 $521.80M 36.14%
2018 $383.27M -8.47%
2017 $418.73M -15.31%
2016 $494.40M 859.98%
2015 $51.50M 192.79%
2014 $17.59M -182.99%
2013 $-21.20M -981.31%
2012 $2.40M -112.99%
2011 $-18.51M -493.30%
2010 $4.71M -45.74%
2009 $8.67M 709.23%
2008 $1.07M -93.04%
2007 $15.40M 107.42%
2006 $7.42M 610.69%
2005 $1.04M 72.62%
2004 $605.05K -110.58%
2003 $-5.72M -392.76%
2002 $1.95M -72.00%
2001 $6.97M 18.03%
2000 $5.91M 0.00%
유사 기업 또는 경쟁사의 수익